top of page
LATEST NEWS
Orforglipron Weight-Loss Pill Trial Results: Eli Lilly Reports 12.4% Body Weight Reduction, Shares Fall 15%
Eli Lilly’s once-daily oral weight-loss pill, orforglipron, helped patients lose 12.4% of their body weight in a Phase 3 trial, but fell short of rival Wegovy’s results. The announcement sent Lilly shares down 15%, the company’s steepest drop in 25 years, despite meeting all primary and secondary endpoints and showing improvements in heart health markers.
Aug 11
Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Advance Gene Editing for Heart Disease
Eli Lilly has announced its $1.3 billion acquisition of Verve Therapeutics, a leading biotech company specializing in gene editing for cardiovascular diseases. This strategic move aims to accelerate the development of one-time gene therapies using base editing technology, targeting high-risk heart disease patients. The deal marks a significant step forward in Eli Lilly’s expansion into precision genetic medicine.
Jul 20
Capricor's Shares Drop After FDA Rejects Deramiocel Cell Therapy for Heart Disease in DMD
Capricor Therapeutics experienced a major setback after the FDA rejected its cell therapy, Deramiocel, for treating heart disease in Duchenne muscular dystrophy (DMD) patients. The decision led to a 30% drop in Capricor’s stock and highlighted the need for more efficacy data. Deramiocel, which uses cardiac-derived stem cells, aims to regenerate heart tissue and slow cardiomyopathy progression in DMD. Capricor plans to resubmit its application with additional clinical data lat
Jul 16
LEARN MORE
GENE TECH TIMES
The Future Has Arrived
Orforglipron Weight-Loss Pill Trial Results: Eli Lilly Reports 12.4% Body Weight Reduction, Shares Fall 15%
Eli Lilly’s once-daily oral weight-loss pill, orforglipron, helped patients lose 12.4% of their body weight in a Phase 3 trial, but fell short of rival Wegovy’s results. The announcement sent Lilly shares down 15%, the company’s steepest drop in 25 years, despite meeting all primary and secondary endpoints and showing improvements in heart health markers.
Aug 11
Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Advance Gene Editing for Heart Disease
Eli Lilly has announced its $1.3 billion acquisition of Verve Therapeutics, a leading biotech company specializing in gene editing for cardiovascular diseases. This strategic move aims to accelerate the development of one-time gene therapies using base editing technology, targeting high-risk heart disease patients. The deal marks a significant step forward in Eli Lilly’s expansion into precision genetic medicine.
Jul 20
Capricor's Shares Drop After FDA Rejects Deramiocel Cell Therapy for Heart Disease in DMD
Capricor Therapeutics experienced a major setback after the FDA rejected its cell therapy, Deramiocel, for treating heart disease in Duchenne muscular dystrophy (DMD) patients. The decision led to a 30% drop in Capricor’s stock and highlighted the need for more efficacy data. Deramiocel, which uses cardiac-derived stem cells, aims to regenerate heart tissue and slow cardiomyopathy progression in DMD. Capricor plans to resubmit its application with additional clinical data lat
Jul 16
FDA Rejects Ultragenyx's Gene Therapy for Rare Disease - Sanfilippo Syndrome
Ultragenyx has received an FDA rejection for its experimental gene therapy targeting Sanfilippo syndrome, a rare and fatal pediatric neurodegenerative disorder. The FDA cited concerns over efficacy data, delaying approval for the treatment. The decision is a major setback for families awaiting a one-time gene therapy option to address the root cause of this rare disease. Ultragenyx plans to work with regulators to resolve the issues and continue advancing its gene therapy pip
Jul 16
Biogen’s Salanersen SMA Treatment Shows Promise After Gene Therapy
Biogen’s investigational drug, Salanersen, shows strong potential as a once-yearly treatment for spinal muscular atrophy (SMA), even after gene therapies like Zolgensma. Early trial results reveal slowed neurodegeneration and improved motor milestones in children. With reduced neurofilament levels and notable functional gains, Salanersen is heading directly into Phase 3 trials, signaling a possible breakthrough in SMA care and a promising alternative to existing therapies lik
Jul 1
bottom of page